Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlumasc Group Regulatory News (ALU)

Share Price Information for Alumasc Group (ALU)

Share Price is delayed by 15 minutes
Get Live Data
240.00    5.00 (2.13%)
Bid:
235.00
Ask:
245.00
Spread: 10.00 (4.255%)
Market Cap: £86.30m
ALU Live PriceLast checked at - London Stock Exchange

Intraday Alumasc Group Share Chart

Trading Statement

19 Jan 2021 07:00

RNS Number : 0821M
Alumasc Group PLC
19 January 2021
 

19 January 2021

THE ALUMASC GROUP PLC

("ALUMASC")

TRADING UPDATE FOR SIX MONTHS ENDED 31 DECEMBER 2020

 

Alumasc, the premium building products, systems, and solutions Group, today provides a trading update for the six months ended 31 December 2020, ahead of publication of its half-year results on Thursday 4 February 2021.

Our absolute focus continues to be the safety of our employees, customers, suppliers, and sub-contractors as we continue to manage with the Covid-19 pandemic and the latest lockdown guidelines.

Record Half Year Performance

Further to our AGM Trading Update on 22 October 2020, which reported a strong performance in the first quarter, we are very pleased to report that conditions in our markets have remained positive and that the Group's trading performance has continued through to the end of the first half of the financial year, with a record profit for the period being achieved. On an unaudited basis, for the first six months of the year:

· Revenue increased 11% versus the prior year to £45.6m

· Underlying PBT increased significantly, from £2.3m to £6.0m

· Cash generation has also been strong in the first half, with net bank debt reducing from £4.3m at 30 June 2020 to £0.2m at 31 December 2020.

 

Pleasingly, all our divisions have contributed to the strong performance. While trading in the period includes an element of catch-up demand following the UK's first national lockdown and has benefitted from a range of Government support for the construction industry, our businesses have also been successful in winning market share and have been further supported by encouraging export sales. Additionally, the restructuring during FY2020, which provided £2.4 million in annual cost savings, benefitted margins. Levolux also continues to respond well to the business's turnaround plan, achieving a profit in each month of the first half of this financial year.

Outlook

The business has entered H2 with good momentum, a healthy forward sales position, and a well-capitalised balance sheet, creating the potential to deliver a strong result for the year. Nevertheless, we remain mindful of the continued economic uncertainties, particularly the risk of disruption to our business and markets in the near term as a result of the on-going pandemic and the establishment of efficient cross-border goods movement following the entry into the Free Trade Agreement with the EU. Conditions in our markets, particularly in the new build housing and RMI sectors, have been very supportive coming into the second half and we would anticipate demand remaining good through the coming months. We are also continuing to monitor the potential impact of changes to UK Government incentives within the housebuilding industry, notably around the current Help to Buy Scheme being extended beyond 28 February 2021 and Stamp Duty and changes here may affect our final quarter, albeit the potential impact is difficult to predict. However, we are encouraged by the UK's accelerating rollout of vaccines and mass testing, which should provide some counterbalance in our markets. Overall, this has been a most encouraging performance by Alumasc in the first half and there is an excellent platform to deliver sustainable shareholder value.

Paul Hooper, CEO, commented, "It is very encouraging to see Alumasc's achievement of a double digit growth in revenues and also a double digit return on sales and H1 has absolutely shown the great potential for the Group. In light of the businesses' momentum and strong cash conversion, a resumption of Alumasc's previous dividend policy is being considered by the Board."

This announcement contains inside information.

Enquiries:

Paul Hooper, CEO

Helen Ashton, Group Company Secretary

+ 44 (0) 1536 383844

+ 44 (0) 1536 383812

 

Peel Hunt (Broker)

Mike Bell + 44 (0)207 418 8831

 

finnCap (NOMAD)

Julian Blunt + 44 (0)207 220 0561

Camarco:

Ginny Pulbrook + 44 (0)203 757 4992

Tom Huddart + 44 (0)203 757 4991

Email: alumasc@camarco.co.uk

 

 

Notes to Editors:

Alumasc is a UK-based supplier of premium building products, systems and solutions. Almost 80% of group sales are driven by building regulations and specifications (architects and structural engineers) because of the performance characteristics offered.

 

The Group has three business segments with strong positions and brands in their individual markets. The three segments are: Water Management; Building Envelope; and Housebuilding Products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSRLFITLIL
Date   Source Headline
20th Sep 201911:29 amRNSNotice of AGM
20th Sep 20197:00 amRNSDirectorate Change
11th Sep 201912:10 pmRNSDirector/PDMR Shareholding
5th Sep 20197:00 amRNSDirectorate Changes
5th Sep 20197:00 amRNSFull Year Results
17th Jul 201910:52 amRNSNotice of Results
28th Jun 201911:00 amRNSUpdate on Levolux strategy
25th Jun 20197:00 amRNSAIM Admission
21st Jun 20198:00 amRNSSchedule One update - The Alumasc Group Limited
20th Jun 20195:30 pmRNSAlumasc Group
14th Jun 20197:00 amRNSTrading Update
3rd Jun 20199:24 amRNSTotal Voting Rights
23rd May 201911:55 amRNSResult of General Meeting
9th May 20193:53 pmRNSDirector/PDMR Shareholding
3rd May 20192:37 pmRNSDirector/PDMR Shareholding
30th Apr 20193:00 pmRNSSchedule One - The Alumasc Group plc
26th Apr 20197:00 amRNSPROPOSED ADMISSION TO TRADING ON AIM
23rd Apr 201910:13 amRNSDirector/PDMR Shareholding
23rd Apr 201910:13 amRNSDirector/PDMR Shareholding
28th Mar 20199:51 amRNSDirector/PDMR Shareholding
5th Feb 20193:03 pmRNSDirector/PDMR Shareholding
31st Jan 20197:00 amRNSHalf-year Report
15th Jan 20197:00 amRNSBoard Changes
14th Jan 20191:30 pmRNSInterim Results Announcement Date
19th Dec 201810:30 amRNSChange of auditor
26th Nov 201811:14 amRNSDirector/PDMR Shareholding
8th Nov 201811:30 amRNSDirector/PDMR Shareholding
8th Nov 201811:26 amRNSDirector/PDMR Shareholding
2nd Nov 20187:00 amRNSAppointment of Non-Executive Director
1st Nov 20187:00 amRNSSale of Facades Business
25th Oct 20184:48 pmRNSResults of AGM
25th Oct 20187:00 amRNSAGM trading update
25th Oct 20187:00 amRNS2018 AGM Trading Statement
11th Sep 20187:00 amRNSFULL YEAR RESULTS ANNOUNCEMENT
21st Aug 20189:26 amRNSNotice of Results
2nd Jul 20182:39 pmRNSDirectorate Change
24th May 20182:54 pmRNSDirector/PDMR Shareholding
15th May 20187:00 amRNSTrading Statement
4th Apr 20181:55 pmRNSDirector/PDMR Shareholding
28th Mar 201812:12 pmRNSHolding(s) in Company
22nd Mar 20184:50 pmRNSDirector/PDMR Shareholding
22nd Mar 20189:16 amRNSDirector/PDMR Shareholding
22nd Mar 20189:15 amRNSDirector/PDMR Shareholding
20th Mar 20182:05 pmRNSDirector/PDMR Shareholding
14th Mar 20187:00 amRNSTrading Statement
23rd Feb 20189:30 amRNSHolding(s) in Company
15th Feb 201810:31 amRNSDirector/PDMR Shareholding
15th Feb 201810:30 amRNSDirector/PDMR Shareholding
12th Feb 20183:00 pmRNSDirector/PDMR Shareholding
12th Feb 20183:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.